Selected article for: "antiviral activity and cell activity"
Author: William E. Diehl; Mehmet H. Guney; Pyae Phyo Kyawe; Judith M. White; Massimo Pizzato; Jeremy Luban
Title: Influence of different glycoproteins and of the virion core on SERINC5 antiviral activity
  • Document date: 2019_9_24
    • ID: 9dybtdi2_7
    Snippet: Importantly, HIV-1 particles pseudotyped with vesicular stomatitis virus (VSV) G or Ebola virus glycoprotein are resistant to SERINC5 antiviral activity (17, 18, 24) . These initial observations suggest a correlation between the location of viral fusion and sensitivity to SERINC5 activity, with glycoproteins that mediate fusion at the cell surface (Env from HIV-1 and amphotropic MLV [A-MLV]) being sensitive and those that mediate fusion in endo-l.....
    Document: Importantly, HIV-1 particles pseudotyped with vesicular stomatitis virus (VSV) G or Ebola virus glycoprotein are resistant to SERINC5 antiviral activity (17, 18, 24) . These initial observations suggest a correlation between the location of viral fusion and sensitivity to SERINC5 activity, with glycoproteins that mediate fusion at the cell surface (Env from HIV-1 and amphotropic MLV [A-MLV]) being sensitive and those that mediate fusion in endo-lysosomal compartments . CC-BY-NC-ND 4.0 International license is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.1101/780577 doi: bioRxiv preprint (VSV-G and Ebola GP) being resistant (17, 24) . Taken together these results indicate that the virion glycoprotein is a viral determinant of sensitivity to SERINC5.

    Search related documents:
    Co phrase search for related documents
    • antiviral activity and cell surface: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral activity and Ebola virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral activity and Ebola virus glycoprotein: 1, 2, 3
    • antiviral activity and International license: 1, 2, 3, 4, 5, 6, 7, 8
    • antiviral activity and sensitivity viral determinant: 1
    • antiviral activity and sensitivity viral fusion: 1
    • antiviral activity and stomatitis virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral activity and vesicular stomatitis virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral activity and viral determinant: 1, 2
    • antiviral activity and viral fusion: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral activity and virion glycoprotein: 1
    • cc NC ND International license and cell surface: 1, 2, 3, 4, 5
    • cc NC ND International license and Ebola virus: 1, 2, 3, 4, 5
    • cc NC ND International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc NC ND International license and stomatitis virus: 1
    • cc NC ND International license and vesicular stomatitis virus: 1
    • cc NC ND International license and viral determinant: 1
    • cc NC ND International license and viral fusion: 1, 2, 3, 4
    • cell surface and Ebola virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25